You are here

2011

Original articles

Lupberger J*, Zeisel MB*, Xiao F, Thumann C, Fofana I, Zona L, Davis C, Mee CJ, Turek M, Gorke S, Royer C, Fischer B, Zahid MN, Lavillette D, Fresquet J, Cosset FL, Rothenberg SM, Pietschmann T, Patel AH, Pessaux P, Doffoel M, Raffelsberger W, Poch O, Mckeating JA, Brino L, Baumert TF. EGFR and EphA2 are host factors for hepatitis C virus entry and targets for antiviral therapy. Nat. Med., 2011, 17, 589-95. *Authors contributed equally.

Barth H, Rybczynska J, Patient R, Choi Y, Sapp RK, Baumert TF, Krawczynski K, Liang TJ. Both innate and adaptive immunity mediate protective immunity against hepatitis C virus infection in chimpanzee. Hepatology, 2011, 54, 1135-48.

Habersetzer F, Bain C, Toh L, Maynard-Muet M, Leroy V, Zarsky JP, Feray C, Baumert TF, Bronowicki JP, Doffoel M, Bonnefoy JY, Limacher JM, Trepo C, Inchauspe G, Honnet G. A poxvirus-based vaccine is safe and induces antiviral T cell responses with decrease of viral load in patients with chronic hepatitis C. Gastroenterology, 2011, 141, 890-99.

Syder AJ, Lee H, Zeisel MB, Grove J, Soulier E, Macdonald J, Chow S, Chang J, Baumert TF, Mckeating JA, Mckelvy J, Wong-Staal F. Small molecule scavenger receptor BI antagonists are potent HCV entry inhibitors. J. Hepatol., 2011, 54, 48-55.

Ehrhardt M, Leidinger P, Keller A, Baumert T, Diez J, Meese E, Meyerhans A. Profound differences of microRNA expression patterns in hepatocytes and hepatoma cell lines commonly used in hepatitis C virus studies. Hepatology, 2011, 54, 1112-3.

Brimacombe CL, Grove J, Meredith LW, Hu K, Syder AJ, Flores MV, Timpe JM, Krieger SE, Baumert TF, Tellinghuisen TL, Wong-Staal F, Balfe P, Mckeating JA. Neutralizing antibody resistant hepatitis C virus cell-to-cell transmission. J. Virol., 2011, 85, 596-605.

Laperche S, Bouchardeau F, Andre-Gamier E, Thibault V, Roque-Afonso AM, Trimoulet P, Colimon R, Duverlie G, Leguillou-Guillemette H, Lunel F, Bouvier-Alias M, Pawlotsky JM, Henquell C, Schvoerer E, Stoll-Keller F, Chaix ML, Branger M, Gaudy-Graffin C, Rosenberg AR, Pozzetto B, Vallet S, Baazia Y, Izopet J, Lefrere JJ. Interpretation of real-time PCR results for hepatitis C virus RNA when viral load is below quantification limits. J. Clin. Microbiol., 2011, 49, 1113-5.

Reviews, editorials etc.

Barth H. Insights into the role of interferon lambda in hepatitis C virus infection. J. Hepatol., 2011, 54, 844-7.

Zeisel MB, Fofana I, Fafi-Kremer S, Baumert TF. Hepatitis C virus entry into hepatocytes: molecular mechanisms and targets for antiviral therapies. J. Hepatol., 2011, 54, 566-76.

Schuster C, Lefèvre M, Baumert TF. Triglyceride synthesis and hepatitis C virus production - identification of a novel host factor as antiviral target. Hepatology, 2011, 53, 1046-8.

Robinet E, Baumert TF. A first step towards a mouse model for hepatitis C virus infection containing a human immune system. J. Hepatol., 2011, 55, 718-20.

Zeisel MB, Da Costa D, Baumert TF. Opening the door to hepatitis C virus infection in genetically humanized mice. Hepatology, 2011, 54, 1873-5.

Turek M, Lupberger J, Baumert TF, Zeisel MB. Sésame, ouvre-toi : régulation de l’entrée du virus de l’hépatite C. Médecine Science, 2011, 27, 929-31.